加拿大批准为产后抑郁症首次口服药物,在短期使用天数内有效。 Canada approves first oral drug for postpartum depression, effective in days with short-term use.

加拿大卫生部批准了Zurzuvae zuranolone(Zurzuvae),这是首次专门为中度至重度产后抑郁症提供的口服药物,这一疾病影响到五分之一的新生儿母亲。 Health Canada has approved zuranolone (Zurzuvae), the first oral medication specifically for moderate to severe postpartum depression, a condition affecting up to one in five new mothers. 该药物每天服用14天,针对受荷尔蒙变化影响的脑受体,可在三天内减少症状,受益时间最长45天。 The drug, taken daily for 14 days, targets brain receptors influenced by hormonal changes and can reduce symptoms in as few as three days, with benefits lasting up to 45 days. 美国、英国和欧盟批准,它为传统抗抑郁药物提供了更快的替代品。 Approved in the U.S., U.K., and EU, it offers a faster alternative to traditional antidepressants. 常见副作用包括沉睡和头晕,促使提供咨询意见以避免母乳喂养,并在早期治疗期间得到支助。 Common side effects include drowsiness and dizziness, prompting advice to avoid breastfeeding and have support during early treatment. 加拿大卫生部发现药物安全和有效,如按指示使用,其益处大于风险。 Health Canada found the drug safe and effective, with benefits outweighing risks when used as directed.